Curapath published a new article exploring the challenges of choosing the drug delivery vehicle for therapy through LNPs and PNPs.
Published
Signal category
Research & Knowledge
Quote
“After a well-deserved summer break, we are back with a new article exploring this challenge through two of the delivery systems we know best: LNPs and PNPs.”
— Curapath team
Company
Curapath
Leading Next Generation Non-viral Gene Delivery to Improve People´s Lives
- Industry
- Pharmaceutical Manufacturing
- Location
- Valencia, ES
- Company size
- 97 employees
Curapath, is a global CDMO specialized in the tailored design, development, and GMP manufacturing of cutting-edge polymer and lipid-based drug delivery systems. Our customers benefit from our unique expertise, operational excellence and technical solutions in polymer nanoparticles (PNPs) and lipid nanoparticles (LNPs) along with their essential components. In addition, we have extensive experience in drug conjugation and cross-linking, to increase stability, reduce toxicity, and enhance bioactivity. At Curapath, we stand as your partner from discovery stages to commercial GMP scale-up. With our dedicated support, expertise, and state of the art manufacturing capabilities, we assure you a guaranteed path for your drug to navigate through clinical development and reach commercialization seamlessly Your success is our commitment
Founded 2013